Thomas P. Blackburn
Directeur/Membre du Conseil chez Umecrine Cognition AB
Profil
Thomas P.
Blackburn is currently the Director at Umecrine Cognition AB since 2017.
Previously, he held positions such as Acting CEO & Vice President-Clinical Development at Helicon Therapeutics, Senior Director-Medical Affairs at Lundbeck Research USA, Director at GSK Plc, and Vice President-Drug Development Operations at Synaptics, Inc. Blackburn received his undergraduate and doctorate degrees from The University of Manchester.
Postes actifs de Thomas P. Blackburn
| Sociétés | Poste | Début |
|---|---|---|
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | 05/09/2017 |
Anciens postes connus de Thomas P. Blackburn
| Sociétés | Poste | Fin |
|---|---|---|
| GSK PLC | Directeur/Membre du Conseil | - |
Lundbeck Research USA, Inc.
 Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Directeur Technique/Scientifique/R&D | - |
| SYNAPTICS INCORPORATED | Directeur des opérations | - |
Helicon Therapeutics, Inc.
 Helicon Therapeutics, Inc. BiotechnologyHealth Technology Helicon Therapeutics, Inc. developed drugs and other therapeutic products. It products include HT-0712 and HT-2157 which are used for the treatment of memory impairment. The company was founded in July 1997 and was headquartered in San Diego, CA. | President | - |
Formation de Thomas P. Blackburn
| The University of Manchester | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SYNAPTICS INCORPORATED | Electronic Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Lundbeck Research USA, Inc.
Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Helicon Therapeutics, Inc.
Helicon Therapeutics, Inc. BiotechnologyHealth Technology Helicon Therapeutics, Inc. developed drugs and other therapeutic products. It products include HT-0712 and HT-2157 which are used for the treatment of memory impairment. The company was founded in July 1997 and was headquartered in San Diego, CA. | Health Technology |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Health Technology |
